Processa Pharmaceuticals Inc PCSA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PCSA is a good fit for your portfolio.
News
-
Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference
-
Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting
-
Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference
-
Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference
-
Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule
-
Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering
-
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
-
Processa Pharmaceuticals Shares More Than Double After Completing Safety Evaluation of Cancer Treatment
Trading Information
- Previous Close Price
- $2.27
- Day Range
- $2.27–2.46
- 52-Week Range
- $2.04–18.00
- Bid/Ask
- $2.40 / $2.43
- Market Cap
- $4.04 Mil
- Volume/Avg
- 166,036 / 157,612
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on the development of drug products that are intended to improve the survival and quality of life for patients who have an unmet medical need. The company's lead product, PCS499 is an oral tablet that is an analog of an active metabolite of an already approved drug. It focuses on fibrotic related diseases such as focal segmental glomerulosclerosis, idiopathic pulmonary fibrosis. Its pipeline products comprise PCS6422, PCS12852, and PCS100.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 15
Valuation
Metric
|
PCSA
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.41 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
PCSA
Financial Strength
Metric
|
PCSA
|
---|---|
Quick Ratio | 8.31 |
Current Ratio | 9.57 |
Interest Coverage | — |
Quick Ratio
PCSA
Profitability
Metric
|
PCSA
|
---|---|
Return on Assets (Normalized) | −94.07% |
Return on Equity (Normalized) | −106.30% |
Return on Invested Capital (Normalized) | −107.28% |
Return on Assets
PCSA
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Qgfrzkln | Nmsy | $570.1 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Jrbnpknmm | Fcyhz | $108.0 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Dpbysknp | Wvyfspx | $105.6 Bil | |
MRNA
| Moderna Inc | Gjmyptcck | Bxmb | $40.8 Bil | |
ARGX
| argenx SE ADR | Lnvbxrcx | Kfmr | $23.5 Bil | |
BNTX
| BioNTech SE ADR | Mwhtpft | Xjw | $21.9 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Zgnqnpd | Jyhtlc | $18.8 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Gvcmffpk | Tbbdg | $16.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Qjvqryfkzh | Lcwnhp | $13.6 Bil | |
INCY
| Incyte Corp | Hlchqmlrt | Jkcpm | $12.8 Bil |